Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 1/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycinebetaine SCHEMBL6135201 | 0.98 | CPT2 (0.44) | CPT2CPT1ATSHRLMNAALDH1A1 | |
| Glycinebetaine SCHEMBL6051974 | 0.89 | CPT2 (0.50) | CPT2CPT1ATSHRLMNAALDH1A1 | |
| Glycinebetaine SCHEMBL7147184 | 0.86 | TSHR (0.46) | CPT2CPT1ATSHRLMNAALDH1A1 | |
| Valine SCHEMBL273485 | 0.86 | SLC7A5 (0.58) | CPT2CPT1ATSHRLMNAALDH1A1 | |
| Valine SCHEMBL17272580 | 0.86 | SLC7A5 (0.58) | CPT2CPT1ATSHRLMNAALDH1A1 | |
| Glycinebetaine SCHEMBL9075162 | 0.84 | TP53 (0.50) | CPT2CPT1ATSHRLMNAALDH1A1 | |
| Glycinebetaine SCHEMBL272555 | 0.83 | GSR (0.39) | CPT2CPT1ATSHRALDH1A1SLC7A5 | |
| Leucine SCHEMBL4947120 | 0.83 | SLC7A5 (0.64) | CPT2CPT1ATSHRSLC7A5SLC1A3 | |
| Glycinebetaine SCHEMBL6673018 | 0.81 | TSHR (0.50) | CPT2CPT1ATSHRLMNAALDH1A1 | |
| Glycinebetaine SCHEMBL1846390 | 0.81 | SLC22A16 (0.50) | CPT2CPT1ATSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129291-A1 | METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACID AND AMINO ACIDS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025132533-A1 | COMPOSITION COMPRISING AN ALIPHATIC ACID OR SALT THEREOF, AN ANTIOXIDANT, A SPECIFIC COMPOUND SUCH AS BETAINE AND AT LEAST ONE PYRIDINE DERIVATIVE | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129302-A1 | COMPOSITION FOR TREATING KERATIN FIBERS AND METHOD FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129284-A1 | COMPOSITIONS AND METHODS FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129288-A1 | COMPOSITIONS AND METHODS FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129292-A1 | METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACID AND AMINO ACIDS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129294-A1 | METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACID AND AMINO ACIDS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025132928-A1 | PROCESS FOR LIGHTENING KERATIN FIBERS USING A PEROXYGENATED SALT, AN OSMOLYTE AND A HYDROXYLATED POLYCARBOXYLIC ACID | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129290-A1 | METHODS FOR TREATING KERATIN FIBERS IN A DYEING PROCESS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129295-A1 | COMPOSITIONS AND METHODS FOR TREATING HAIR | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2020154387-A1 | COMPOSITIONS FOR TREATING CITRUS DISEASE AND PROMOTING YIELD INCREASE IN ROW CROPS | SPOGEN BIOTECH INC. (US) | 2020-07-30 | — | — | WO | claimed |
| WO-2018150077-A1 | BETAINE BIOMARKERS FOR NUTRITIONAL STATUS, NUTRITIONAL REGIMEN, ENDOGENOUS METABOLISM, OR RISK OF CARDIOVASCULAR OR METABOLIC DISEASES | AFEKTA TECHNOLOGIES OY (FI) | 2018-08-23 | — | — | WO | claimed |
| EP-1446096-A1 | TOPICAL COMPOSITIONS CONTAINING ENZYMES STABILISED WITH INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-18 | — | — | EP | claimed |
| EP-1446090-A2 | COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH CERTAIN OSMO-PROTECTANTS AND METHODS FOR USING SUCH COMPOSITIONS IN PERSONAL CARE | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-18 | — | — | EP | claimed |
| WO-2004035818-A1 | USE OF OSMOLYTES TO HEAT STABILISE LUCIFERASE AND/OR APYRASE | BIOTAGE AB (SE) | 2004-04-29 | — | — | WO | claimed |
| US-20030175232-A1 | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | THE PROCTER & GAMBLE COMPANY | 2003-09-18 | — | — | US | claimed |
| US-20030157088-A1 | Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care | THE PROCTOR & GAMBLE COMPANY | 2003-08-21 | — | — | US | claimed |
| WO-2003041667-A2 | COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH CERTAIN OSMO-PROTECTANTS AND METHODS FOR USING SUCH COMPOSITIONS IN PERSONAL CARE | THE PROCTER & GAMBLE COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2003041680-A1 | TOPICAL COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| WO-1998046074-A1 | IMPROVING THE PRESERVABILITY OF PLANTS | CULTOR CORPORATION (FI) | 1998-10-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175232-A1 | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | TREH, CUTA, LPO | CPT2 2713/4885CPT1A 996/4885TSHR 3649/4885 |
| US-20030157088-A1 | Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care | CUTA, LCT, TYR | CPT2 4665/4885CPT1A 3602/4885TSHR 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.